Trusted Resource for Clinical Trials, Protocols & Progress
Immunotherapy Phase 2 Trial Considerations Designing and Managing Phase 2 Trials for Immunotherapy: Key Considerations Introduction Immunotherapy has transformed the treatment landscape for various cancers, autoimmune diseases, and chronic infections. As these therapies work by modulating the body’s immune system, Phase 2 trials for immunotherapies require distinct strategies that account for delayed responses, novel endpoints,…
The Role of Pharmacometrics in Dose Prediction for Phase 1 Using Pharmacometrics to Predict First-in-Human Dosing in Early Trials Introduction Predicting a safe and pharmacologically relevant starting dose is one of the most critical decisions in early-phase clinical development. Pharmacometrics—the science of applying mathematical modeling and simulation to pharmacokinetic (PK) and pharmacodynamic (PD) data—plays a…
Read More “The Role of Pharmacometrics in Dose Prediction for Phase 1” »
Decentralized and Hybrid Trial Models in Phase 2 Implementing Decentralized and Hybrid Clinical Trial Models in Phase 2 Studies Introduction The traditional site-centric model of clinical trials is evolving rapidly. With the advancement of digital health technologies and the impact of global health crises like COVID-19, sponsors and regulators have embraced decentralized clinical trials (DCTs)…
Read More “Decentralized and Hybrid Trial Models in Phase 2” »
Phase 1 Studies for Inhaled Therapies: PK, PD, and Device Considerations Designing Early-Phase Clinical Trials for Inhaled Drug Products Introduction Inhalation drug delivery offers fast, localized therapeutic action with minimal systemic exposure. Used in respiratory diseases like asthma and COPD, and increasingly in systemic applications such as vaccines or insulin, inhaled therapies pose unique clinical…
Read More “Phase 1 Studies for Inhaled Therapies: PK, PD, and Device Considerations” »
Real-World Data Integration in Phase 2 Study Planning Incorporating Real-World Data into Phase 2 Study Planning: A Practical Guide Introduction As clinical development evolves, the use of Real-World Data (RWD) is expanding beyond post-marketing surveillance into earlier phases of research. In Phase 2, RWD can enhance trial design, support site selection, inform endpoint development, and…
Read More “Real-World Data Integration in Phase 2 Study Planning” »
Cardiac Safety in Phase 1: QTc and Intensive ECG Monitoring Evaluating QTc Risk and ECG Changes in Early Clinical Development Introduction Cardiac safety assessment is a critical component of Phase 1 clinical trials, particularly for new chemical entities and biologics with unknown off-target effects. One of the primary concerns is QT interval prolongation—a surrogate marker…
Read More “Cardiac Safety in Phase 1: QTc and Intensive ECG Monitoring” »
Platform and Basket Trials in Phase 2 Innovative Phase 2 Designs: Understanding Platform and Basket Trials Introduction Traditional Phase 2 trials typically evaluate one treatment in one patient population using a fixed design. However, the evolution of precision medicine, rare disease drug development, and oncology research has led to the rise of adaptive, multi-arm trial…
Phase 1 Study Designs for Cell and Gene Therapies Designing Early Phase Trials for Complex Cell and Gene Therapy Products Introduction Cell and gene therapies (CGTs) represent one of the most revolutionary frontiers in medicine, offering curative potential for genetic disorders, cancers, and rare diseases. However, these therapies bring profound challenges when it comes to…
Read More “Phase 1 Study Designs for Cell and Gene Therapies” »
Preparing for Phase 2B End-of-Phase Meeting with Regulators How to Prepare for the End-of-Phase 2B Meeting with Regulatory Authorities Introduction The End-of-Phase 2B (EOP2B) meeting is a pivotal milestone in clinical drug development. It provides an opportunity for sponsors to align with regulatory agencies—particularly the U.S. FDA—on the adequacy of Phase 2 findings and the…
Read More “Preparing for Phase 2B End-of-Phase Meeting with Regulators” »
Documentation and GCP Compliance in Phase 2 Maintaining Essential Documentation and GCP Compliance in Phase 2 Clinical Trials Introduction Phase 2 clinical trials are pivotal in determining whether a drug or intervention should advance to large-scale Phase 3 trials. As such, maintaining Good Clinical Practice (GCP) compliance and meticulous clinical documentation is not only a…
